Navigation Links
Jan-Åke Gustafsson leads team with $5.2M for prostate cancer research
Date:4/1/2011

HOUSTON, April 1, 2011 A pair of University of Houston (UH) researchers and their colleagues will begin work to develop new methods for treating the most severe form of prostate cancer thanks to $5.2 million in grants recently awarded by the Cancer Prevention and Research Institute of Texas (CPRIT).

Renowned hormone researcher Dr. Jan-ke Gustafsson, Robert A. Welch Professor in UH's biology and biochemistry department and director of the Center for Nuclear Receptors and Cell Signaling (CNRCS), will oversee the multi-investigator award. The work will be an interdisciplinary collaboration with researchers from the CNRCS at UH, The Methodist Hospital Research Institute (TMHRI) and the University of Texas at El Paso (UTEP).

As the founding researchers of CNRCS, Gustafsson and UH biology and biochemistry professor Margaret Warner will collaborate with Paul Webb of TMHRI and Marc Cox of UTEP to explore new treatments for prostate cancer. Gustafsson, who discovered a previously unknown estrogen receptor during the mid-1990s, is internationally recognized as a leading authority on hormone receptors and will lead the group in the discovery of innovative approaches to slowing the growth of early-stage cancers and combating late-stage cancers.

"More than 200,000 new cases of prostate cancer are diagnosed annually, affecting one in six men. In approximately one-third of diagnosed cases, the disease spreads and invades other tissues to become life-threatening," Gustafsson said. "Through this grant, we will be able to open the door for new and better therapies. Our early efforts have yielded promising results, and we look forward to building on our previous successes."

Prostate cancer grows and survives on male hormones called androgens, and current treatments target these naturally occurring hormones. This can result in negative and harmful side effects. In the most severe and recurrent forms, the cancer can become resistant to this therapy, at which point treatment options are extremely limited.

Armed with decades of experience in hormone research, Gustafsson and Warner will test plant-derived and synthetic chemicals resembling hormones to prevent and combat prostate cancer. The team also plans to develop drugs that target new areas of the androgen signaling system and work differently from existing therapies. Their collaboration with Webb and Cox will allow the team to expedite testing the feasibility of the new methods of treatment.

"This important award is an indication of UH's continuing commitment to research excellence and reflects the emphasis we place on finding real solutions to health-related problems," said UH President Renu Khator.

These grants, announced March 24, are part of $116 million awarded by CPRIT to 22 cancer research and commercialization projects at 16 Texas-based institutions and private companies. This is the second time the CNRCS has benefitted from CPRIT funding. Anders Strom, another researcher within the center, received funding from the institute last year for a collaborative project with TMHRI to develop new therapies for treating secondary tumors that may result from current breast cancer treatments.

In 2007, the state dedicated $3 billion to establish CPRIT and invest in groundbreaking cancer research and prevention programs in Texas. The institute focuses on expediting the innovation and commercialization of research, increasing the potential for breakthroughs and enhancing access to evidence-based prevention programs and services.


'/>"/>

Contact: Lisa Merkl
lkmerkl@uh.edu
713-743-8192
University of Houston
Source:Eurekalert  

Related biology news :

1. FSU researchers discovery leads to $1.5 million grant, potential new treatment of liver fibrosis
2. How neuronal activity leads to Alzheimers protein cleavage
3. Exposing chicks to maternal stress leads to long-term reproductive success
4. TECNALIA leads five projects within the VII Framework Program
5. Personalized medicine: Innovative online journal leads the way
6. Mayo Clinic research on tamoxifen leads to recommendation for CYP2D6 gene test
7. Study of placenta unexpectedly leads to cancer gene
8. Game of two halves leads to brain asymmetry
9. Transportation fuels of the future: Nottingham leads the way
10. Concordia University leads academic team for national Cellulosic Biofuels Network
11. Elephant shark genome sequence leads to discovery of color perception in deep-sea fish
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Jan-Åke Gustafsson leads team with $5.2M for prostate cancer research
(Date:1/25/2016)... , Jan. 25, 2016  Glencoe Software, the world-leading ... and publication industries, will provide the data management solution ... (NPSC). ... Phenotypic analysis measures the ... organisms, allowing comparisons between states such as health and ...
(Date:1/20/2016)... Jan. 20, 2016 A market that just ... benefit from the explosion in genomics knowledge. Learn all ... Research. A range of dynamic trends are pushing market ... personalized medicine - pharmacogenomics - pathogen evolution - next ... markets - greater understanding of the role of genetic ...
(Date:1/15/2016)... Puerto Rico , Jan. 15, 2016 ... big and small to find new ways to ensure ... culture. iOS and Android ... based on biometrics, transforming it into a hardware authorization ... that users swipe their fingerprint on their KodeKey enabled ...
Breaking Biology News(10 mins):
(Date:2/10/2016)... 2016  The Maryland House of Delegates and House ... University of Maryland School of Medicine Dean E. ... Maryland Medical System President and CEO Robert Chrencik ... highest honor given to the public by the leader ... Reece and Mr. Chrencik for their contributions to ...
(Date:2/10/2016)... 2016 ASAE is introducing a hybrid membership ... (AMC) the option of joining or renewing through an ... by staff size, every employee in any size association ... reap all available member benefits.   John ... membership options will allow organizations of any size and ...
(Date:2/10/2016)... -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company ... for the treatment of prostate, brain, lung, head and ... for the second quarter and six months of fiscal ... --> --> Revenue was $1.19 ... ended December 31, 2015, a 12% increase compared to ...
(Date:2/10/2016)... , Feb. 10, 2016  Matchbook, Inc., ... for fast growing biotech companies, announced today the ... Procurement Strategic Advisor. Jim brings nearly 25 years ... and procurement, having spent nearly two decades in ... Chain/Logistics and Procurement at Genzyme and, most recently ...
Breaking Biology Technology: